{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T01:45:18Z","timestamp":1776303918482,"version":"3.50.1"},"reference-count":78,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1080\/14740338.2024.2412236","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T11:43:32Z","timestamp":1728042212000},"page":"1393-1404","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Safety considerations for drugs newly approved for treating acute myeloid leukemia"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-3587","authenticated-orcid":false,"given":"Aleksandra","family":"Go\u0142os","sequence":"first","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, Lodz, Poland"},{"name":"Department of Hematooncology, Copernicus Memorial Hospital, Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6427-4532","authenticated-orcid":false,"given":"Joanna","family":"G\u00f3ra-Tybor","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, Lodz, Poland"},{"name":"Department of Hematooncology, Copernicus Memorial Hospital, Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-6357","authenticated-orcid":false,"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, Lodz, Poland"},{"name":"Department of General Hematology, Copernicus Memorial Hospital, Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.11.017"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850"},{"key":"e_1_3_6_8_1","unstructured":"UFaD A. National cancer institute: drug approved for leukemia. [cited 2024 Apr 24]. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/leukemia#3"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2171860"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00464-6"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6112"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188888"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0060"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002140"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117344"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014901"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00292-7"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0312-9"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2234"},{"key":"e_1_3_6_23_1","unstructured":"Administration USFaD. Enasidenib prescribing information. 2017 [cited 2024 May 4]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209606s000lbl.pdf"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011583"},{"key":"e_1_3_6_25_1","unstructured":"Administration UFaD. Gemtuzumab ozogamicin prescribing information. 2024 [cited 2024 Apr 28]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761060lbl.pdf"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004856"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-325050"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4892(03)00083-3"},{"key":"e_1_3_6_29_1","unstructured":"Administration UFaD. Gemtuzumab ozogamicin prescribing information. 2006 [cited 2024 Apr 28]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/021174s020lbl.pdf"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404434"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0604"},{"key":"e_1_3_6_32_1","unstructured":"Administration UDa F. Vyxeos (daunorubicin and cytarabine) prescribing information. 2017 [cited 2024]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209401s000lbl.pdf"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00134-4"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00361-8"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00558-5"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0607"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0876"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1399312"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0779-0"},{"key":"e_1_3_6_41_1","unstructured":"Administration USFa R. Midostaurin prescribing information. 2017 [cited 2024 May 6]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207997s000lbl.pdf"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-869453"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.449.449"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04448-w"},{"key":"e_1_3_6_45_1","unstructured":"Administration USFa D. FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. 2018 [cited 2024 May 4]. Available from: https:\/\/www.fda.gov\/drugs\/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutation"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12113647"},{"key":"e_1_3_6_47_1","unstructured":"Administration USFaD. Gilteritinib prescribing information. 2018 [cited 2024 May 4]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211349s000lbl.pdf"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144139"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014586"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01911"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186785"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14022"},{"key":"e_1_3_6_53_1","unstructured":"Administration UFaD. Quizartinib prescribing information. 2023 [cited 2024 Aug 18]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216993s000lbl.pdf"},{"key":"e_1_3_6_54_1","unstructured":"Administration USFa D. FDA approves quizartinib for newly diagnosed acute myeloid leukemia. 2023 [cited 2024 May 4]. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-828269"},{"key":"e_1_3_6_57_1","unstructured":"Administration USFa D. FDA approves venetoclax for CLL or SLL with or without 17 p deletion after one prior therapy. 2018 [cited 2024 May 3]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-venetoclax-cll-or-sll-or-without-17-p-deletion-after-one-prior-therapy"},{"key":"e_1_3_6_58_1","unstructured":"Administration USFa D. FDA approves venetoclax for CLL and SLL. 2019 [cited 2024 May 3]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-venetoclax-cll-and-sll"},{"key":"e_1_3_6_59_1","unstructured":"Administration UFaD. Venetoclax prescribing information 2016. [cited 2024 May 3]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208573s000lbl.pdf"},{"key":"e_1_3_6_60_1","unstructured":"Maiti A Konopleva MY. How we incorporate venetoclax in treatment regimens for acute myeloid leukemia. (1540-336X (electronic))."},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-383752"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07737"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13019"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0365"},{"key":"e_1_3_6_65_1","unstructured":"Administration UFaD. Glasdegib prescribing information. 2018 [cited 2024 May 3]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210656s000lbl.pdf"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10860"},{"key":"e_1_3_6_67_1","unstructured":"Administration USFaD. Ivosidenib prescribing information. 2018 [cited 2024 May 7]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/211192_s008lbl.pdf"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0813-2"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00494-0"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01844-1"},{"key":"e_1_3_6_71_1","unstructured":"Administration UFaD. Olutasidenib: prescribing information. 2023 [cited 2024 Aug 18]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215814s000lbl.pdf"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2289176"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146944"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167412"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188961"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01061"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167316"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010721"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006303"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017014175"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2024.2412236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T12:32:31Z","timestamp":1731414751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2024.2412236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":78,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1080\/14740338.2024.2412236"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2024.2412236","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}